ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Armistice Capital acquired more shares of ImmunityBio as EMA recommended ANKTIVA approval and Q3 2025 product revenue surged ...
Published on January 6, 2026, in Volume 2 of the Immunity & Inflammation journal, the review begins by underscoring Professor Taniguchi's ...
New research suggests that the secret to longevity may lie in an immune system that strongly resists the effects of aging ...
The immune system remains seriously out-of-whack—in an inflammatory state of overactivation and impaired ...
The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...
Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback